Name: Atheronova Inc
Address: 2301 Dupont Dr Ste 525, Irvine, CA, 92612-7525, USA
Telephone: (949) 476-1100

It is believed that regression and stabilization of plaque will become the new gold standard in the treatment and prevention of cardiovascular disease. If the Company's premise is confirmed, this would introduce the first clinically proven method to regress soft, vulnerable plaque.

AtheroNova, through its wholly-owned subsidiary, AtheroNova Operations, Inc., is a biotechnology company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans. The Company plans to develop multiple applications for its compounds to be used in pharmaceutical grade products for the treatment of atherosclerosis. Atherosclerosis -- or plaque buildup in the arteries -- is the leading cause of heart attacks, stroke, and peripheral vascular disease.

The Company has developed intellectual property, covered by a patent and patents pending for a class of naturally occurring compounds, which use certain pharmacological compounds uniquely for the treatment of atherosclerosis; the primary cause of various cardiovascular diseases. Atherosclerosis occurs when cholesterol or fats are deposited on arterial walls and form as plaques. Such deposits are theorized as occurring due to weaknesses or imperfections in the arterial walls. Another theory is that these plaques develop at the site of arterial inflammations.

The current standard of care is dominated by statin drugs in multiple dose levels, which can be introduced with an expectation that once a patient was started on a statin drug, they would be a patient for life. Such prescription characteristics have made statin drugs the most successful drug family in the history of medicine. AHRO-001, AtheroNova's primary compound, is slated to compete with statins that largely lower cholesterol and stabilize plaque, whereas pre-clinical results for AHRO-001 have demonstrated sharply more treatment results than just cholesterol reduction, such as lowering risk of heart attack and stroke.

AtheroNova has conducted a number of pre-clinical studies and is preparing for Phase I human clinical trials to demonstrate the efficacy of its IP as first demonstrated in a pilot study conducted in 2009. The IP uses naturally occurring bile salts normally found in the digestive tract to dissolve, or delipidize, the portions of the soft, vulnerable plaque that are accessible through the fibrous cap. This delipization process breaks down plaque deposits into molecules small enough to pass safely through the fibrous cap without causing harm to the fibrous cap itself.

Atheronova Inc

Business Info

Contact Business

Company Summary

Similar Businesses Nearby

Competitive Landscape

Payments Accepted

Hours

Photos

Business Credit Report

Facebook

Twitter

Yelp

Customer Resources

Our Company

Our Network

Site Links